This phase I dose escalation study is intended to define the dose limiting toxicities and maximum tolerated dose of ADH-1 in three separate studies with the chemotherapy treatments Docetaxel, Carboplatin or Capecitabine.
“ADH-1 has been well tolerated in clinical studies thus far, and we look forward to exploring its potential synergistic activity with some commonly-used chemotherapies,” said Robert Raju, of Dayton Oncology & Hematology
“Recent preclinical data have shown that the combination effects of chemotherapy and ADH-1 are dramatically enhanced and unpredicted compared to the results of either agent alone,” said William Peters, Chairman and CEO of Adherex.
The company went on to say that if ADH-1 was able to increase chemotherapy’s anti-tumor activity, the market opportunity for the drug would increase as most oncology products now use combination therapy.
“We believe that ADH-1 will be most easily incorporated into the current treatment framework as a combination with either chemotherapeutic agents or other biologics,” said CEO William Peters.